Cumulative 2017/2018 Season Lot Release Status (Updated 11/30/2017)
Flu vaccine lots that have been released by FDA and are available for distribution by the manufacturers. For information on flu vaccine distribution schedules, please contact the manufacturers directly.
| Manufacturer | Total Number of Lots Released by FDA |
|---|---|
|
Afluria
Seqirus Pty. Ltd. |
23 |
|
Afluria Quadrivalent
Seqirus Pty. Ltd. |
38 |
|
Fluad
Seqirus, Inc. |
13 |
|
Fluarix Quadrivalent
GlaxoSmithKline Biologicals |
36 |
|
Flublok
Protein Sciences Corporation |
2 |
|
Flublok Quadrivalent
Protein Sciences Corporation |
6 |
|
Flucelvax Quadrivalent
Seqirus, Inc. |
48 |
|
FluLaval Quadrivalent
ID Biomedical Corporation of Quebec |
31 |
|
FluMist Quadrivalent
MedImmune, LLC |
3 |
|
Fluvirin
Seqirus Vaccines Limited |
13 |
|
Fluzone High Dose
Sanofi Pasteur, Inc. |
28 |
|
Fluzone Quadrivalent
Sanofi Pasteur, Inc. |
36 |
FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Rockville, Maryland, on March 9, 2017, to select the influenza viruses for the composition of the influenza vaccine for the 2017-2018 U.S. influenza season. During this meeting, the advisory committee reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics of recent influenza isolates, serological responses to 2016-2017 vaccines, and the availability of candidate strains and reagents.
The committee recommended that the trivalent formulation influenza vaccines for the U.S. 2017-2018 influenza season contain the following:
- an A/Michigan/45/2015 (H1N1) pdm09-like virus
- an A/Hong Kong /4801/2014 (H3N2)-like virus
- a B/Brisbane/60/2008-like virus (B/Victoria lineage).
The committee also recommended that quadrivalent influenza vaccines contain the above three strains and the following additional B strain:
- a B/Phuket/3073/2013-like virus (B/Yamagata lineage)